Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health & Wellness Today New York.
Press releases published on June 26, 2025

Kobi Halperin Launches Summer 2025 Collection at The Hub with Exclusive Kickoff Event Supporting Cancer Research
Fashion Forward, Philanthropy First: A Benefit for Samuel Waxman Cancer Research Foundation NEW YORK, NY, UNITED STATES, June 26, 2025 /EINPresswire.com/ -- Fashion meets philanthropy this summer in the Hamptons, with the arrival of The Hub’s newly …

Soapy USA Inc Partners with ASL Salerno Healthcare Network to Revolutionize Hand Hygiene Compliance.
Deployment across 11 major hospitals in ED, ICU, NICU, Gynecology and Anesthesiology-OR department NEW YORK, NY, UNITED STATES, June 26, 2025 /EINPresswire.com/ -- Earlier this year, Soapy Care, a global leader in automated hand-hygiene monitoring and …

Grammy-Nominated R&B Powerhouse LaTocha will Perform at 'Your Health in Full Bloom'
R…

New Study Finds Breakthrough Knee & Back Pain Treatment Cuts Musculoskeletal Costs by 81% for Major Health Provider
A large risk-bearing provider in NJ cut MSK costs by 81%, saving $9M in 20 months, using Apos®—a non-invasive, foot-worn device for chronic knee …

Mother Goose Health and Nourish Join Forces to Deliver Seamless, Whole-Person Maternal Care
Mother Goose Health partners with Nourish to add expert nutrition support to its comprehensive digital maternity care management platform. NEW YORK, NY, UNITED STATES, June 26, 2025 /EINPresswire.com/ -- Mother Goose Health, a digital platform …

The Albany Job Fair 2025 July 16th Features 1p-2p Veterans Hours and 2p-6p Public Hours
The Albany Job Fair returns Wednesday, July 16, 2025, from 1pm to 6pm at the Holiday Inn Express, 400 Old Loudon Road, Latham, NY ALBANY, NY, NY, UNITED STATES, June 26, 2025 /EINPresswire.com/ -- The Albany Job Fair returns Wednesday, July 16, 2025, …

Earth Science Tech, Inc. Reports Fiscal Year-End Results for March 31, 2025, with Revenue Exceeding $33.1 Million and Net Profit of $3.2 Million
Miami, FL, June 26, 2025 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or “Company”), a strategic holding company, focused on value creation through the acquisition, operational optimization, and management of its operating businesses, …

Extendicare Announces Renewal of Normal Course Issuer Bid
MARKHAM, Ontario, June 26, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that the Toronto Stock Exchange (the “TSX”) has approved the renewal of Extendicare’s normal course issuer bid (“NCIB”). Under …

Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the closing of its …

Kane Biotech Announces Conversion of Demand Loan from Insider into an Unsecured Convertible Debenture and Annual General Meeting Voting Results
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, June 26, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) announces that today it has completed its previously …

Teva Releases Q2 2025 Aide Memoire
TEL AVIV, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2025 Aide Memoire is available on the “Investors” page on its website. Q2 2025 Aide Memoire Teva has prepared this …

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
First-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers with initial data expected in Q4 2025 Marks the first submitted Clinical Trial Application (CTA) advancing ProQR’s Axiomer™ …

Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025
NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders …

Lifeward Announces Closing of $2.6 Million Public Offering
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or …

Basel Medical Obtains Waiver of Lock-Up for Potential Strategic Fund Raising
Singapore, June 26, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”), today announced that Cathay Securities, Inc., as the representative of the several underwriters of the Company’s initial public offering, has granted its …

Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025
TARRYTOWN, N.Y., June 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2025 financial and operating results on Friday, August 1, 2025, before the U.S. financial markets open. …

Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem’s Hormone-Free, On-Demand Prescription Contraceptive Gel
Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of 2026 Tech transfer underway with validation batch …

Achieve Life Sciences Announces Proposed Underwritten Public Offering
SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of …

Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades
Omnicom cross-agency collaboration to drive technology-led, innovative launch strategy Partnership brings together promising science, top-tier talent, and advanced technologies to enable a faster, smarter, and more effective path to address a critical …

Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation
Smoking, the leading cause of preventable death and disease, continues to affect nearly 29 million adults in the U.S. alone If approved, cytisinicline will be the first new FDA-approved pharmacotherapy option for nicotine dependence in two decades More …